Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aesculap US to distribute IsoTis bone matrix:

This article was originally published in Clinica

Executive Summary

IsoTis OrthoBiologics has appointed Aesculap US as a non-exclusive distributor of its demineralised bone matrix product, DynaGraft II DBM. The Center Valley, Pennsylvania-based subsidiary of German multinational Aesculap is to market the product under the brand name ProSpace DBM through its direct sales force. With Aesculap's spinal franchise growing at over 30% per year, it is hoped the move will indirectly increase IsoTis's share of the US spinal surgery market, says the Lausanne, Switzerland-based firm.

You may also be interested in...



France Moves To Bolster Drug Supplies Hit By COVID-19

France has announced a number of emergency measures to protect drug supplies threatened by the spread of the coronavirus.

Sun, Accord, Amneal And Apotex Donate Hydroxychloroquine

Major generics companies have donated hydroxychloroquine sulfate doses for research and treatment of coronavirus. Companies are also donating hand sanitizer and personal protective equipment and are preparing to ramp up manufacturing and production.

Coronavirus Update: Inovio Begins Phase I Trials of DNA Vaccine, Fast-Track Drug Dialogue Continues

Inovio forges ahead into Phase I trials with DNA-based vaccine candidate, but can it prove skeptics wrong?

Topics

UsernamePublicRestriction

Register

MT060233

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel